AzTrials
AzTrials

Lower Limbs Peripheral Arterial DiseaseQFRNCT06516315

Feasibility Study of an Angiographic Quantitative Flow Ratio-guided Endovascular Procedure in Patients With Lower Limbs Peripheral Arterial Disease.

A study testing Preoperative ultrasound examination. and Peroperatoire angiography procedure and QFR analysis in people with Lower Limbs Peripheral Arterial Disease, run by Fondation Hôpital Saint-Joseph at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The main objective of this study is to explore the feasibility of using the angiographic Quantitative Flow Ratio (QFR) as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease. This is a prospective feasibility study. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Lower Limbs Peripheral Arterial Disease
What is being tested?
Preoperative ultrasound examination. and Peroperatoire angiography procedure and QFR analysis
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
1 siteFrance
Study dates
29 Apr 2024to 24 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient with symptomatic Rutherford stage 2 to 6 AOMI with an indication for endovascular revascularization
  • Patient with a simple lesion (TASC A) and short stenosis of the superficial femoral artery
  • Patient affiliated to a health insurance system
  • French-speaking patient
  • Patient with free, informed and express oral consent

Who cannot join

  • Renal failure patients with GFR \< 30 ml/min
  • Patient deprived of liberty
  • Patients under court protection
  • Pregnant or breast-feeding patients

Trial locations and contacts

1 site in 1 country.

Michèle LOHORE contact

+ 331 44127883

crc@ghpsj.fr

France1 site, 1 recruiting
  • Hôpital Paris Saint-Joseph - 185 Rue Raymond Losserand

    Paris, Île-de-France Region, 750014

    MICHELE LOHORE, crc@ghpsj.fr

    Recruiting

Other trials in France

About this study

The main objective of this study is to explore the feasibility of using the angiographic Quantitative Flow Ratio (QFR) as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease.

This is a prospective feasibility study. We aim to include 35 patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery. Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.

Read the detailed description

Approximately 202 million people are affected with lower extremity artery disease (LEAD) worldwide, of whom almost 40 million are living in Europe. LEAD usually appears after the age of 50 years, with an exponential increase after the age of 65. This rate reaches around 20% by the age of 80. In most studies, the proportion of symptomatic LEAD is 1:3 to 1:5 of all LEA.

The global burden of LEAD is considerable. In 2010, the years of life lost due to LEAD were estimated at 31.7, 15.1, and 3.7 years per 100,000 inhabitants in Western, Central, and Eastern Europe, respectively.

During the two last decade, indications of endovascular approach of femoropopliteal lesions have dramatically increased, to become the gold standard with a first endo strategy approach. In 2000, endovascular treatment was recommended for stenosis ≤ 5cm or occlusions ≤ 3cm. Today, the guidelines suggest endo approach for lesion until 25 cm In 2019, in France, 50 000 patients underwent an endovascular femoral popliteal revascularization, and drug eluting devices (Stents or Balloons). According to the Excellence in Peripheral Artery Disease Registry, early stent occlusion is about 5% during the 6 first months after procedure. Success rate of endovascular procedure is high, but many thrombosis are due to incomplete endovascular treatment, leading to early re-occlusion. Usually, quality and success assessment are made by the operator, based on images provided by a single plan angiography. Vascular surgeons face a lack of devices helping us to appreciate the quality of our revascularization per procedure. Endovascular ultrasounds (IVUS) or Optical Coherence Tomography(OCT) are not reimbursed in many countries. These devices are quite expensive and, like the FFR, require the introduction of dedicated devices into the arteries, thus increasing procedure's duration.

Similar situation can be seen in patients undergoing coronary percutaneous coronary intervention (PCI), current evidence indicates post-PCI suboptimal results. However, the combination of quantitative vessel analysis (QVA) with angiography-derived fractional flow reserve (FFR) assessment has shown promising improvements in PCI outcomes. A notable non-invasive solution for angiography derived FFR is Quantitative Flow Ratio (QFR), which includes quantitative vessel analysis (QVA) reporting significant enhancement in revascularization therapy.

Extending its potential benefits, QFR emerges as a non-invasive and cost-effective solution to improve revascularization outcomes for lower extremities.

MAIN OBJECTIVE The main objective of this study is to explore the feasibility of using QFR as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease.

METHODS:

  1. Study design and Population This is a prospective feasibility study. We aim to include 35 patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery (TASC A, Rutherford stage 2 to 6). Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
  2. Clinical variables:
  • Age
  • Sex
  • Height/Weight
  • Previous medical history
  • Rutherford classification
  • TASC lesion (only for sfa)
  • Procedure: - Type of treatment
  • Stents (type, length, diameter, number)
  • Amount of contrast
  • Xray duration
  • Xray Dose (Gy)
  • Technical success
  • Outcomes: 30 days patency
  1. Angiography procedure and acquisition protocol Selective PCI will be performed using standard catheterization according to European society of Cardiology guidelines for lower extremity artery disease. At least two projections angles separated at least 25 degrees were acquired for the optimal view of the lesions. Details of the acquisition protocol are described in appendix B.
  2. QCA and QFR analysis The 3D QCA and QFR analysis will be performed using a research version of software package QFR 2.2. QFR allows to match two diagnostic angiographic projections and create a 3D reconstruction of the interrogated vessel. From this reconstruction the following parameters will be derived: lesions length, QFR, delta(△) QFR, % diameter of stenosis, minimum lumen diameter, residual QFR, QFR pullback curve and derivative of QFR pullback curve (dQFR/ds).
Being tested
Preoperative ultrasound examination., Peroperatoire angiography procedure and QFR analysis
Keywords
Lower Limbs Peripheral Arterial Disease, endovascular procedure, angiographic Quantitative Flow Ratio

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Preoperative ultrasound examination.Procedure or surgery

    Preoperative ultrasound examination performed the day before or the day of surgery.

  • Peroperatoire angiography procedure and QFR analysisProcedure or surgery

    Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.

Study groups in NCT06516315
Study groupRoleWhat they receive
qfrExperimentalPatients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery (TASC A, Rutherford stage 2 to 6) : * Preoperative ultrasound, performed the day before or the day of surgery * Intraoperative angiography performed immediately prior to revascularization (routine care procedure whose duration is extended by research) * Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.
Receives: Procedure: Preoperative ultrasound examination.; Procedure: Peroperatoire angiography procedure and QFR analysis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Preoperative systolic velocity peak and intraoperative QFR

    Systolic velocity peak measured by preoperative ultrasound, performed the day before or the day of surgery, and QFR measured intraoperatively, immediately before the revascularization procedure.

    Measured: Day -1, Day 0

Secondary outcomes (8)
  1. Percentage of stenosis

    Percentage of stenosis measured by preoperative ultrasound, performed the day before or the day of surgery.

    Measured: Day -1, Day 0

  2. Occurrence of a Major Adverse Limb Event (MALE)

    Occurrence of a Major Adverse Limb Event (MALE) at 1 month post-op (D30): Acute ischemia OR Major amputation OR Re-intervention on revascularized limb (excluding minor amputation).

    Measured: Day 30

  3. Re-hospitalization

    Re-hospitalization for any reason at 1 month post-procedure (D30).

    Measured: Day 30

  4. Revascularization

    Revascularization (endovascular or surgical) of the treated area (Target Lesion Revascularization (TLR)) defined by re-intervention on the target lesion, including 1 cm above and below the target lesion.

    Measured: Day 30

  5. Rutherford classification

    Rutherford classification at 1 month post-op.

    Measured: Day 30

  6. Dosimetry and dose of contrast medium

    Dosimetry and dose of contrast medium injected during the procedure (D0).

    Measured: Day 0

  7. Procedure envisaged by surgeon

    Procedure envisaged by surgeon 1 and procedure envisaged by surgeon 2 after reading the QFR.

    Measured: Day 0

  8. Creatinine levels and glomerular filtration rate

    Preoperative (D0) and postoperative (D5 and D30) creatinine levels and glomerular filtration rate.

    Measured: Day 5, Day 30

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2024
  2. Study start29 Apr 2024
  3. Primary completion24 Apr 2025 (estimated)
  4. Study completion24 May 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
Prospective feasibility study
Masking
None (open label)
Enrolment
35 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06516315
Sponsor's protocol ID
684_QFR
Other IDs
2024-A00022-45
Acronym
QFR
Status last verified
Jul 2024
First submitted
10 Jul 2024
Last updated
23 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Preoperative ultrasound examination. and Peroperatoire angiography procedure and QFR analysis in people with Lower Limbs Peripheral Arterial Disease, run by Fondation Hôpital Saint-Joseph at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Michèle LOHORE (+ 331 44127883, crc@ghpsj.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Preoperative systolic velocity peak and intraoperative QFR (time frame: Day -1, Day 0). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in